Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21497149 | 1.00 | PDE2A (0.42) | PDE2AEPHX2ALDH1A1KMT2APIM1 | |
| SCHEMBL15332685 | 0.81 | PDE2A (0.45) | PDE2AEPHX2ALDH1A1KMT2APIM1 | |
| SCHEMBL21495026 | 0.80 | CHRM2 (0.42) | ALDH1A1PIM1PIM2GAAMAPT | |
| SCHEMBL474179 | 0.80 | CHRM2 (0.42) | ALDH1A1PIM1PIM2GAAMAPT | |
| SCHEMBL1676518 | 0.79 | PDE2A (0.54) | PDE2AEPHX2ALDH1A1MAPTKIF11 | |
| SCHEMBL11215946 | 0.78 | PDE2A (0.49) | PDE2AEPHX2ALDH1A1KMT2AMAPT | |
| SCHEMBL2092438 | 0.78 | PDE2A (0.49) | PDE2AEPHX2ALDH1A1KMT2APIM1 | |
| SCHEMBL646645 | 0.78 | PDE2A (0.49) | PDE2AEPHX2ALDH1A1KMT2AMAPT | |
| SCHEMBL15571330 | 0.78 | PDE2A (0.42) | PDE2AEPHX2ALDH1A1KMT2APIM1 | |
| SCHEMBL9570882 | 0.78 | PDE2A (0.42) | PDE2AEPHX2ALDH1A1KMT2APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888255-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015028960-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-03-05 | — | — | WO | disclosed |
| EP-2822928-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reddy's Laboratories Ltd. (IN) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014031936-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2013131408-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR.REDDY'S LABORATORIES LTD. (IN) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013033037-A2 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2283018-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2265606-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2190844-A2 | IMIDAZO[L,2-a]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2155738-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| CN-1980906-A | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2007-06-13 | — | — | CN | disclosed |
| WO-2007056496-A1 | OXAZOLE AND THIAZOLE PPAR MODULATOR | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| EP-1644375-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | PDE2A 904/4885EPHX2 3187/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.